Online inquiry

IVTScrip™ mRNA-Anti-HBV, GC-1102(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7522MR)

This product GTTS-WQ7522MR is a type of mRNA modified with 5-Methyl-CTP & Pseudo-UTP, which ecodes the monoclonal antibody that targets HBV gene. The antibody can be applied in Hepatitis B research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NC_003977.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 944569
UniProt ID Q2F515
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-HBV, GC-1102(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7522MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10686MR IVTScrip™ mRNA-Anti-TNFSF13B, LymphoStat-B(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA LymphoStat-B
GTTS-WQ13420MR IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA PRO132365
GTTS-WQ10176MR IVTScrip™ mRNA-Anti-SELP, LC1004-002(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LC1004-002
GTTS-WQ2658MR IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG 655
GTTS-WQ9019MR IVTScrip™ mRNA-Anti-MST1R, IMC RON-8(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IMC RON-8
GTTS-WQ15386MR IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA TRU-016
GTTS-WQ4634MR IVTScrip™ mRNA-Anti-LAG3, BMS-986016(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-986016
GTTS-WQ756MR IVTScrip™ mRNA-Anti-LOXL2, AB0024(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AB0024
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW